XML 76 R62.htm IDEA: XBRL DOCUMENT
v3.21.1

Equity (Details) |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 08, 2020 | May 03, 2019 | Feb. 08, 2019 $ / shares shares | Oct. 01, 2016 | May 06, 2016 | Feb. 08, 2016 shares | Feb. 08, 2016 shares | Nov. 21, 2020 USD ($) shares | Nov. 19, 2020 $ / shares shares | Aug. 31, 2019 USD ($) $ / shares | Jun. 30, 2019 USD ($) shares | Feb. 28, 2017 | Aug. 26, 2016 | Mar. 21, 2016 $ / shares shares | Feb. 17, 2016 shares | Mar. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2020 USD ($) $ / shares shares | Dec. 31, 2019 USD ($) shares | Mar. 12, 2020 $ / shares shares | Jun. 24, 2017 USD ($)
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Forward split ratio |  |  |  |  |  |  |  |  |  |  |  |  |  | On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the “Forward Stock Split”) and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. |  |  |  |  |  |
Common stock, par value (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.001 |  | $ 0.001 | $ 0.001 |  |  |
Common stock, authorized |  |  |  |  |  |  |  |  |  |  |  |  |  | 360,000,000 |  | 100,000,000 | 100,000,000 |  |  |
Agreement, description |  |  |  |  | the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company’s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. |  |  |  |  |  |  | the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company’s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company’s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit). | the Company issued 1,468,750 shares (“Shares”) of the Company’s Common Stock, par value $0.001 (the “Offering”) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. |  |  |  |  |  |  |
Financial amendment, description |  | the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (“FINRA”). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company’s common stock were exchanged for 17,693,625 shares of the Company’s Common Stock. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 24,420,526 | 24,420,526 |  |  |
Consulting fees (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,514,800 |  |
Stock subscription receivable (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,934,620 |  | $ 3,160,360 |  |
Due to related parties (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 312,152 | $ 288,445 |  |  |
Due to related parties consideration (in Dollars) | $ |  |  |  |  |  |  |  |  |  | $ 4,872,340 |  |  |  |  |  |  |  |  |  |
Common stock price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  | $ 7.00 |  |  |  |  |  |  |  |  |  |
Warrant issued |  |  |  |  |  |  |  |  | 200,000 |  |  |  |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  | $ 2.25 |  |  |  |  |  |  |  |  |  |  |
Warrant term |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,384,615 |  |  |  |
Aggregate common stock shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 915,856 |  |  |
2016 Equity Incentive Plan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 157,050 |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  |  |  |
Share Exchange Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  | 164,387,376 | 164,387,376 |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  | 52,336,000 | 52,336,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Share Exchange Agreement One [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  | 166,273,921 | 166,273,921 |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  | 52,936,583 | 52,936,583 |  |  |  |  |  |  |  |  |  |  |  |  |
Share Exchange Agreement Two [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  | 163,159,952 | 163,159,952 |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  | 51,945,225 | 51,945,225 |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of common shares issued and outstanding |  |  |  |  |  | 79.70% | 79.70% |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of issued share capital |  |  |  |  |  | 100.00% | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Share Exchange Agreement Three [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  | 166,273,921 | 166,273,921 |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  | 52,936,583 | 52,936 |  |  |  |  |  |  |  |  |  |  |  |  |
Share Exchange Agreement Four [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  | 205,519,223 | 205,519,223 |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  | 65,431,144 | 65,431,144 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares, shares |  |  |  |  |  |  |  |  |  |  | 428,571 |  |  |  |  |  |  |  |  |
Consulting agreement, description |  |  |  | On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s Common Stock at $1.00 per share for any amount exceeding $3,000. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |
Euro-Asia Investment & Finance Corp Ltd. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 644,972 |  |
Co-Dev Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Due to related parties (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000
Consulting Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 521,887 |  |  |
Consulting Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PRice per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2 |  |  |
Consulting Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
SaleOfStockPricePerShare |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.68 |  |  |
Kameyama [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares, shares |  |  |  |  |  |  |  | 24,694 |  |  |  |  |  |  |  |  |  |  |  |
Unpaid consulting fees (in Dollars) | $ |  |  |  |  |  |  |  | $ 49,388 |  |  |  |  |  |  |  |  |  |  |  |
Articles of Incorporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, par value (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.001 |
Articles of Incorporation [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, authorized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000 |
Articles of Incorporation [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, authorized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000,000 |
View Trade Securities Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000 |  |  |
Consulting fees (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 135,000 |  |  |
Placement agent agreement, description | Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restricted common shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  |
Consulting Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  | $ 2.9 |  |  |  |  |  |  |  |  |  |  |
Unrestricted common shares |  |  |  |  |  |  |  |  | 50,000 |  |  |  |  |  |  |  |  |  |  |
Non Related Parties [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt conversion, description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | a. Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company’s common stock, and warrants to purchase 159,145 shares of the Company’s common stock. b. Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company’s common stock, and warrants to purchase 154,368 shares of the Company’s common stock. c. C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company’s common stock, and warrants to purchase 162,908 shares of the Company’s common stock. d. KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company’s common stock, and warrants to purchase 126,530 shares of the Company’s common stock. e. Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company’s common stock, and warrants to purchase 192,784 shares of the Company’s common stock. f. KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company’s common stock, and warrants to purchase 120,121 shares of the Company’s common stock. |  |  |  |
Private Placement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregated capital contributions (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,615,331 |  |  |
Number of investors |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45 |  |  |
Number of investors (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2.25 |  |  |
BioLite [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares, shares |  |  | 74,997,546 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
BioKey [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  | 1,642,291 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares, shares |  |  | 29,561,231 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of investors (in Dollars per share) | $ / shares |  |  | $ 1.50 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Aggregate Common Stock Shares. + References No definition available. + Details
Name: | abvcd_AggregateCommonStockShares
Namespace Prefix: | abvcd_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement related description. + References No definition available. + Details
Name: | abvcd_AgreementDescription
Namespace Prefix: | abvcd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Common stock issued after stock split. + References No definition available. + Details
Name: | abvcd_CommonStockIssuedAfterStockSplit
Namespace Prefix: | abvcd_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Common stock issued before stock split. + References No definition available. + Details
Name: | abvcd_CommonStockIssuedBeforeStockSplit
Namespace Prefix: | abvcd_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Consulting agreement description. + References No definition available. + Details
Name: | abvcd_Consultingagreementdescription
Namespace Prefix: | abvcd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvcd_EquityDetailsLineItems
Namespace Prefix: | abvcd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvcd_FinancialAmendmentDescription
Namespace Prefix: | abvcd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Issuance of Common Stock. + References No definition available. + Details
Name: | abvcd_IssuanceOfCommonStock
Namespace Prefix: | abvcd_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | abvcd_NumberOfInvestors
Namespace Prefix: | abvcd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of issued share capital. + References No definition available. + Details
Name: | abvcd_PercentageOfIssuedShareCapital
Namespace Prefix: | abvcd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | abvcd_PlacementAgentAgreementDescription
Namespace Prefix: | abvcd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Restricted Common Shares. + References No definition available. + Details
Name: | abvcd_RestrictedCommonShares
Namespace Prefix: | abvcd_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares
Namespace Prefix: | abvcd_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvcd_StockIssuedValue
Namespace Prefix: | abvcd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of stock subscription receivable. + References No definition available. + Details
Name: | abvcd_StockSubscriptionReceivable
Namespace Prefix: | abvcd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + References No definition available. + Details
Name: | abvcd_StockholderEquityReverseStockSplit
Namespace Prefix: | abvcd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvcd_UnpaidConsultingFees
Namespace Prefix: | abvcd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | abvcd_UnrestrictedCommonShares
Namespace Prefix: | abvcd_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Warrant issued. + References No definition available. + Details
Name: | abvcd_WarrantIssued
Namespace Prefix: | abvcd_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrant term + References No definition available. + Details
Name: | abvcd_WarrantTerm
Namespace Prefix: | abvcd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockSharesAuthorized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586 + Details
Name: | us-gaap_DebtConversionConvertedInstrumentAmount1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The price per share of the conversion feature embedded in the debt instrument. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 5 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870 + Details
Name: | us-gaap_DebtInstrumentConvertibleConversionPrice1
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644 + Details
Name: | us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying amount as of the balance sheet date of obligations due all related parties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.17) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(3),(4)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_DueToRelatedPartiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromContributionsFromAffiliates
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.2(a),(b),(c),(d)) -URI http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 220 -Section 45 -Paragraph 3 -Subparagraph (k) -URI http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268 + Details
Name: | us-gaap_ProfessionalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_PlanNameAxis=abvcd_TwoThousandSixteenEquityIncentivePlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvcd_CodevelopmentagreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvcd_ConsultingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvcd_KameyamaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvcd_ArticlesOfIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvcd_ViewTradeSecuritiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvcd_ConsultingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvcd_NonRelatedPartiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=abvcd_BioLiteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=abvcd_BioKeyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |